AzTrials
AzTrials

Relapsed/Refractory B-Cell NeoplasmsPhase 1NCT07200479

A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms

A Phase 1 study testing CAR T cells chimeric antigen receptor cells in people with Relapsed/Refractory B-Cell Neoplasms, run by Institute of Hematology & Blood Diseases Hospital, China at 3 sites in China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

A Clinical Study to Explore the Safety, Efficacy and Cellular Metabolic Kinetics of CT1194D CAR-T Cells Injection in Patients with Relapsed/Refractory B-Cell Neoplasms Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Relapsed/Refractory B-Cell Neoplasms
What is being tested?
CAR T cells chimeric antigen receptor cells
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
3 sitesChina
Study dates
30 Oct 2025to 30 Dec 2027
Phase
Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • R/R B-NHL Inclusion Criteria：
  • 1. Voluntary participation in the clinical study; I fully understand and are informed of this study and sign the informed consent form; Willing to follow and able to complete all study procedures; 2. Age 18-75 years (inclusive) 3. Histologically or cytologically confirmed diagnosis of R/R B-NHL according to the WHO classification of lymphoid hyperplasia and neoplasms, 5th Edition 2022, including:
  • 1) Cohort A1: large B-cell lymphoma, including diffuse large B-cell lymphoma unspecified (DLBCL, NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, large B-cell lymphoma transformed from follicular lymphoma (FLBL)/Grade 3b FL; 2) Cohort A2: Mantle cell lymphoma (MCL); 3) Cohort B: follicular lymphoma grade 1-3a; 4. Prior Therapy Requirements:
  • Cohort A1: Patients who have previously received standard systemic therapy, including regimens containing anti-CD20 drugs (except CD20 negative) and anthracyclines;
  • Cohort A2: Prior standard systemic therapy, including an anti-CD20 agent (except CD20 negative), an anthracycline-containing regimen, or a BTK inhibitor;
  • Cohort B: previously received standard systemic therapy, including regimens containing anti-CD20 drugs (except CD20 negative) and anthracyclines; 5. Intolerance during the last treatment, or the need for new treatment after the last adequate treatment (at least 2 cycles) or as assessed by the investigator; 6. At least one of the following:
Show all 27Show fewer
  • 1) As measured by CT: Nodal lesions > 1.5 cm in long diameter or extranodal lesions > 1.0 cm in long diameter and measurable in short axis; 2) As measured by PET: FDG uptake fraction of 4 or 5; 8. Eastern Cooperative Oncology Group (ECOG) score 0-1; 9. Participants should meet the following test results (there should be no ongoing supportive care):
  • Hematology: ① Platelet (PLT) ≥ 75 × 109/L (study participants with bone marrow or peripheral blood involvement: PLT ≥ 50 × 109/L), ② Hemoglobin (Hb) ≥ 80 g/L (study participants with bone marrow or peripheral blood involvement: Hb ≥ 60 g/L);
  • Endogenous creatinine clearance ≥ 50 mL/min, or creatinine ≤ 1.5 × ULN (using Cockcroft-Gault formula);
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN, total bilirubin ≤ 1.5 × ULN; If lymphoma invades the liver: AST and ALT ≤ 5 × ULN, total bilirubin ≤ 3.0 × ULN;
  • International normalized ratio (INR) and activated partial thromboplastin time (APTT) were required to be ≤ 1.5 × ULN.
  • Oxygen saturation ≥ 92% in non-oxygen inhalation state;
  • Left ventricular ejection fraction (LVEF) ≥ 50% (LVEF value near the cut-off value can be enrolled after adequate risk assessment by the investigator); 10. Female participants of child-bearing potential must have a negative pregnancy test at the time of screening and before receiving lymphodepletion therapy, be willing to use a highly effective and reliable method of contraception within 1 year after receiving study treatment, and absolutely prohibit egg donation within 1 year after receiving study treatment infusion during the study; A male participant, if sexually active with a female of childbearing potential, is willing to use a highly effective and reliable method of contraception for 1 year after receiving study treatment. All male participants absolutely refrain from donating sperm for 1 year after receiving study treatment infusion during the study.
  • R/R B-ALL Inclusion Criteria：
  • Voluntary participation in the clinical study; I fully understand and are informed of this study and sign the informed consent form; Willing to follow and able to complete all study procedures;
  • Age 18-75 years (inclusive);
  • Morphologically, immunologically, or molecularly confirmed diagnosis of R/R B-ALL (Cohort C) and 1 of the following criteria is met:
  • <!-- -->
  • Patients who did not achieve complete remission after standard induction regimen chemotherapy or had early relapse after complete remission (< 12 months) or late relapse after complete remission (≥ 12 months) and did not achieve complete remission after standard one course of induction regimen chemotherapy and relapsed after 2 or more CR or CRi;
  • For Ph + ALL patients who have not achieved complete remission after receiving at least one TKI treatment in addition to standard induction chemotherapy, or relapsed after complete remission (those who cannot tolerate TKI treatment or have contraindications for TKI treatment, or have T315I mutation are not required to receive TKI treatment); 4. Leukemia cells with positive expression of CD19 and/or CD20 in bone marrow or peripheral blood; 5. Bone marrow cell morphology or peripheral blood indicates blast ratio ≥ 5%; 6. Estimated survival > 12 weeks; 7. Eastern Cooperative Oncology Group (ECOG) score 0-2; 8. Participants should meet the following test results (there should be no ongoing supportive care):
  • <!-- -->
  • Endogenous creatinine clearance ≥ 50 mL/min, or creatinine ≤ 1.5 × ULN (using the Cockcroft-Gault formula);
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN, total bilirubin ≤ 1.5 × ULN; If hepatobiliary involvement: AST and ALT ≤ 5 × ULN, total bilirubin ≤ 3.0 × ULN;
  • International normalized ratio (INR) and activated partial thromboplastin time (APTT) must be ≤ 1.5 × ULN;
  • Oxygen saturation ≥ 92% in non-oxygen inhalation state;
  • Left ventricular ejection fraction (LVEF) ≥ 50% (LVEF values near the cut-off value may be enrolled after adequate risk assessment by the investigator).
  • 9. Female participants of child-bearing potential must have a negative pregnancy test at the time of screening and before receiving lymphodepletion therapy, be willing to use a highly effective and reliable method of contraception for 1 year after receiving study treatment, and absolutely refrain from egg donation for 1 year after receiving study treatment infusion during the study; A male participant, if sexually active with a female of childbearing potential, is willing to use a highly effective and reliable method of contraception for 1 year after receiving study treatment. All male participants absolutely refrain from donating sperm for 1 year after receiving study treatment infusion during the study.

Who cannot join

  • R/R B-NHL Exclusion Criteria：
  • Pregnant or lactating females;
  • Study participants with a history of neurological disease, such as epilepsy, intracranial hemorrhage, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, memory impairment, spinal cord compression, psychiatric disorders or any disease involving the central nervous system, or suspected central nervous system (CNS) metastasis;
  • Presence of HIV, syphilis infection, active hepatitis B virus infection (HBV-DNA above detection limit or positive), or active hepatitis C virus infection (HCV-RNA positive);
  • Current presence of any uncontrolled active infection, including but not limited to active tuberculosis study participants (as judged by the investigator);
  • Known or suspected long-term active EBV infection, known history of HLH;
Show all 43Show fewer
  • The toxicities caused by previous treatment have not recovered to Common Terminology Criteria for Adverse Events (CTCAE 5.0) ≤ Grade 1, except for alopecia and other tolerable events as judged by the investigator;
  • Received autologous stem cell transplantation within 12 weeks before signing the informed consent form; Received allogeneic stem cell transplantation;
  • Prior treatment targeting CD19 (unless the CD19 or CD20 target remains positive);
  • Antineoplastic therapy, including but not limited to cytotoxic therapy, monoclonal antibodies or antibody conjugates, targeted therapy, radiotherapy, epigenetic therapy, or investigational drug therapy, or use of an invasive investigational medical device within 14 days or 5 half-lives (whichever is shorter) prior to cell infusion. Participants are eligible for the study regardless of the end date of radiotherapy if the radiation field covers ≤ 5% bone marrow reserve;
  • Systemic corticosteroids equivalent to > 15 mg/day prednisone within 7 days prior to informed consent, with the exception of topical corticosteroids;
  • Vaccination with live attenuated vaccines, inactivated vaccines or RNA vaccines within 4 weeks prior to signing the informed consent form;
  • Allergy or intolerance to CLD drugs, tocilizumab, or allergy to the components of CT1194D cell infusion preparation (dimethyl sulfoxide/DMSO); Or previous history of other severe allergies such as anaphylactic shock;
  • Study participants with any of the following cardiac conditions:
  • <!-- -->
  • New York Heart Association (NYHA) Class III or IV heart failure;
  • Myocardial infarction, coronary artery bypass grafting, or unstable angina 6 months prior to screening;
  • History of clinically significant uncontrolled arrhythmia, such as ventricular arrhythmia;
  • History of severe non-ischemic cardiomyopathy;
  • Other cardiac disease that, in the opinion of the investigator, may jeopardize the health of the study participant due to participation in this clinical study; 14. Have other severe pulmonary disease that may endanger the life of the study participant as judged by the investigator; 15. Have a second primary malignancy requiring treatment or not in complete remission within the past 2 years, with the exception of successfully treated non-metastatic basal cell or squamous cell skin cancer, non-metastatic carcinoma in situ of the prostate, breast or cervical cancer, non-muscle invasive bladder cancer or thyroid cancer and other low-grade tumors; 16. Study participants with active autoimmune diseases, including but not limited to psoriasis, rheumatoid arthritis, inflammatory bowel disease and other diseases requiring long-term immunosuppressive therapy; 17. Major surgery within 2 weeks before signing the informed consent form, or planning to undergo major surgery during the study or within 4 weeks after the administration of study treatment (excluding cataract and other surgery under local anesthesia); 18. Inability or unwillingness of the participant to comply with the requirements of the study protocol as assessed by the investigator, or for other reasons unsuitable for participation in this clinical study.
  • R/R B-ALL Inclusion Criteria：
  • Pregnant or lactating females;
  • Study participants with a history of neurological disorders, such as epilepsy, intracranial hemorrhage, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, memory impairment, spinal cord compression, psychiatric disorders or any disease involving the central nervous system, or active central nervous system (CNS) leukemia;
  • Presence of HIV, syphilis infection, active hepatitis B virus infection (HBV-DNA above detection limit or positive), or active hepatitis C virus infection (HCV-RNA positive);
  • Current presence of any uncontrolled active infection, including but not limited to active tuberculosis study participants (as judged by the investigator);
  • Known or suspected long-term active EBV infection, known history of HLH;
  • Presence of active systemic autoimmune disease;
  • The toxicities caused by previous treatment have not recovered to Common Terminology Criteria for Adverse Events (CTCAE V5.0) ≤ Grade 1, except for alopecia and other tolerable events as judged by the investigator;
  • Study participants with solitary extramedullary lesions; Study participants with genetic syndromes associated with bone marrow failure states: such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known bone marrow failure syndrome.
  • Study participants who relapsed after treatment with drugs targeting CD19 and/or CD20 prior to screening and who are judged not to benefit by the investigator;
  • Received autologous or allogeneic stem cell transplantation within 3 months before signing the informed consent form; Donor lymphocyte infusion (DLI) within 6 weeks;
  • Active graft-versus-host disease (GVHD) of grade 2-4 within 4 weeks before signing the informed consent form;
  • Antineoplastic therapy, including but not limited to cytotoxic therapy, monoclonal antibodies or antibody conjugates, targeted therapy, radiotherapy, epigenetic therapy, or investigational drug therapy, or use of an invasive investigational medical device within 14 days or 5 half-lives (whichever is shorter) prior to cell infusion. Participants are eligible for the study regardless of the end date of radiotherapy if the radiation field covers ≤ 5% bone marrow reserve;
  • Systemic corticosteroids equivalent to > 15 mg/day prednisone within 3 days prior to cell infusion, except for topical corticosteroids;
  • Vaccination with live attenuated vaccines, inactivated vaccines or RNA vaccines within 4 weeks prior to signing the informed consent form;
  • Allergy or intolerance to CLD drugs, tocilizumab, or allergy to the components of CT1194D cell infusion preparation (dimethyl sulfoxide/DMSO); Or previous history of other severe allergies such as anaphylactic shock;
  • Study participants with any of the following cardiac conditions:
  • <!-- -->
  • New York Heart Association (NYHA) Class III or IV heart failure;
  • Myocardial infarction, coronary artery bypass grafting, or unstable angina 6 months prior to screening;
  • History of clinically significant uncontrolled arrhythmia, such as ventricular arrhythmia;
  • History of severe non-ischemic cardiomyopathy;
  • Other cardiac disease that, in the opinion of the investigator, may jeopardize the health of the study participant due to participation in this clinical study; 17. Have other severe pulmonary disease that may endanger the life of the study participant as judged by the investigator; 18. Have a second primary malignancy requiring treatment or not in complete remission within the past 2 years, with the exception of successfully treated non-metastatic basal cell or squamous cell skin cancer, non-metastatic carcinoma in situ of the prostate, breast or cervical cancer, non-muscle invasive bladder cancer or thyroid cancer and other low-grade tumors; 19. Major surgery within 2 weeks before signing the informed consent form, or planning to undergo major surgery during the study or within 4 weeks after the administration of study treatment (excluding cataract and other surgery under local anesthesia); 20. After organ transplantation; 21. Inability or unwillingness of the participant to comply with the requirements of the study protocol as assessed by the investigator, or for other reasons unsuitable for participation in this clinical study.

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Liang Huang contact

13971600192

huangliang@ihcams.ac.cn

China3 sites

  • China Institute of Hematology and Blood Diseases Hospital

    Tianjin, 301617

    Liang Huang, 13971600192, huangliang@ihcams.ac.cn

  • China Institute of Hematology and Blood Diseases Hospital

    Tianjin, 301617

    Shuhua Yi, 15900265415

  • China Institute of Hematology and Blood Diseases Hospital

    Tianjin, 301617

    Ying Wang, 15900225626

Other trials in China

About this study

Official title: A Clinical Study to Explore the Safety, Efficacy and Cellular Metabolic Kinetics of CT1194D CAR-T Cells Injection in Patients With Relapsed/Refractory B-Cell Neoplasms

A Clinical Study to Explore the Safety, Efficacy and Cellular Metabolic Kinetics of CT1194D CAR-T Cells Injection in Patients with Relapsed/Refractory B-Cell Neoplasms

Read the detailed description

This is a single-arm, open-label, dose exploratory clinical study to evaluate the safety, efficacy, cellular Metabolic Kinetics of CT1194D CAR-T Cells in patients with relapsed/refractory B-cell Non-Hodgkin's Lymphoma (R/R B-NHL) and relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). It is planned to enroll around 20-30 participants.

Being tested
CAR T cells chimeric antigen receptor cells
Medical subject headings
Recurrence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CAR T cells chimeric antigen receptor cellsDrug

    CT1194D cells infusion

Study groups in NCT07200479
Study groupRoleWhat they receive
CAR-T cells chimeric antigen receptor T cellsExperimentalNot described
Receives: Drug: CAR T cells chimeric antigen receptor cells

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To assess the severity and incidence of DLTs, treatment-related adverse events (TRAE), and adverse events of special interest (AESI) after CT1194D infusion

    Measured: 12 months after CT1194D infusion

  2. MTD or dose range

    To explore the maximum tolerated dose (MTD) or dose range of CT1194D

    Measured: Up to 28 days after CAR-T cells infusion

Secondary outcomes (8)

  1. Overall Response Rate (ORR)

    Measured: Evaluate at 4, 8, 12 weeks and 6,9,12month after CAR-T infusion

  2. Complete response rate (CRR)

    Measured: 12 months after CT1194D infusion

  3. Minimal Residual Disease Negative (MRD-) Proportion (R/R B-ALL)

    Measured: 12 months after CT1194D infusion

  4. Duration of response (DOR)

    Measured: 12 months after CT1194D infusion

  5. Time to response (TTR)

    Measured: 12 months after CT1194D infusion

  6. Time to complete response (TTCR)

    Measured: 12 months after CT1194D infusion

  7. Progression-free survival (PFS)

    Measured: 12 months after CT1194D infusion

  8. Overall Survival (OS)

    Measured: 12 months after CT1194D infusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Oct 2025
  2. Study start30 Oct 2025 (estimated)
  3. Primary completion28 Jun 2027 (estimated)
  4. Study completion30 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07200479
Sponsor's protocol ID
IIT2025099
Status last verified
Sep 2025
First submitted
19 Sep 2025
Last updated
1 Oct 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing CAR T cells chimeric antigen receptor cells in people with Relapsed/Refractory B-Cell Neoplasms, run by Institute of Hematology & Blood Diseases Hospital, China at 3 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 27 inclusion and 43 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 1 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Liang Huang (13971600192, huangliang@ihcams.ac.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To assess the severity and incidence of DLTs, treatment-related adverse events (TRAE), and adverse events of special interest (AESI) after CT1194D infusion (time frame: 12 months after CT1194D infusion). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07200479.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in